Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.
Q2 FY26 Earnings Results
-
Revenue from Operations: ₹443.9 crore, up 5.7% YoY and up 10.1% QoQ
-
Gross Profit: ₹308.2 crore, up 7.2% YoY
-
Operating EBITDA: ₹118.8 crore, up 2.5% YoY, margin at 26.8%
-
Profit After Tax (PAT): ₹91.8 crore, up 5.0% YoY and down 1.3% sequentially from Q1 FY26
-
PAT margin: 20.7% (Q2 FY25: 21.1%, Q1 FY26: 23.1%)
-
Domestic revenue grew strongly at 16.9% YoY; international growth more modest
-
Other income contributed ₹33.9 crore (volatile sequentially)
-
Company maintains ₹1,109 crore in net cash as of Sep 30, 2025
-
Ongoing investments in manufacturing capacity and new products
Management Commentary & Strategic Insights
-
Management highlighted record-high quarterly revenue, with robust domestic market momentum and new product launches
-
Acquisitions of PendraCare (Netherlands, cardiology) and Citieffe (Italy, orthopaedics) completed in the quarter, expanding global portfolio
-
Company remains focused on expanding premium/high-margin product segments and operational efficiencies
-
Launched “Polymed Academy of Clinical Excellence” to boost market engagement and brand reputation
-
Cautious outlook on margin due to persistent cost pressures, but long-term optimism from capacity expansion and product pipeline
Q1 FY26 Earnings Results
-
Revenue from Operations: ₹403 crore, up 4.8% YoY
-
Gross Profit: ₹276 crore, up 7.6% YoY
-
Operating EBITDA: ₹106.1 crore, up 2.1% YoY, margin at 26.3%
-
Profit After Tax (PAT): ₹93.1 crore, up 25.5% YoY
-
PAT margin: 20.9%, up 250 bps YoY
-
EPS: ₹9.2, up 19% YoY
-
Growth driven by strong domestic revenue (+20% YoY); export revenue declined 0.9% YoY
-
Company held ₹1,248.6 crore liquidity at June end and invested ₹95 crore in capex for expansion and sustainability initiatives
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.